AP2002002643A0 - 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors - Google Patents

5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors

Info

Publication number
AP2002002643A0
AP2002002643A0 APAP/P/2002/002643A AP2002002643A AP2002002643A0 AP 2002002643 A0 AP2002002643 A0 AP 2002002643A0 AP 2002002643 A AP2002002643 A AP 2002002643A AP 2002002643 A0 AP2002002643 A0 AP 2002002643A0
Authority
AP
ARIPO
Prior art keywords
so2nr4r5
co2r4
compounds
hydrogen
alkylpyrido
Prior art date
Application number
APAP/P/2002/002643A
Inventor
Richard John Booth
Ellen Myra Dobrusin
Peter Laurence Toogood
Scott Norman Vanderwel
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AP2002002643A0 publication Critical patent/AP2002002643A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Disclosed are compounds of the formula (1)wherein: R2 is hydrogen, alkyl, or cycloalkyl: R1 is hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, lower alkynyl, lower alkenyl, nitrile, nitro, -COR4-CO2R4, -CONR4R5, -CONR4OR5, -SO2NR4R5,-SO2NR4R5, -SO2R4, -SO3R4, formula (II), or -NR4R3, Y is N or CR7, R' is lower alkyl, haloalkyl, or aryl, X and Z are independently hydrogen, halogen, lower alkyl, lower alkoxy,trifluoromethyl, hydroxy, nitrile, nitro, -NR4R5, -N(O)R4R5, -NR4R5R4W, -SR4, -C(O)R4,-CO2R4,-CO2R4, -CONR4R5, -SO2NR4R5, -SO2R4, -SO3R4, P(O)(OR4XOR5), -T(CH2),QR4, -C(O)T(CH2),QR4 or -NR4C(O)T(CH2),QR5, m is 1 to 6. These compounds are useful for treating cell proliferative disorders, such as cancer, atherosclerosis, and restenosis. These compounds are potent inhibitors of cyclin-dependent kinases (cdks)and growth factor-mediated kinases
APAP/P/2002/002643A 2000-03-06 2001-01-29 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors AP2002002643A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06
PCT/US2001/002657 WO2001070741A1 (en) 2000-03-06 2001-01-29 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
AP2002002643A0 true AP2002002643A0 (en) 2002-12-31

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2002/002643A AP2002002643A0 (en) 2000-03-06 2001-01-29 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors

Country Status (36)

Country Link
EP (1) EP1268476A1 (en)
JP (1) JP2003528101A (en)
KR (1) KR20020075805A (en)
CN (1) CN1422268A (en)
AP (1) AP2002002643A0 (en)
AR (1) AR034119A1 (en)
AU (1) AU2001233028A1 (en)
BG (1) BG107161A (en)
BR (1) BR0109056A (en)
CA (1) CA2401368A1 (en)
CO (1) CO5280200A1 (en)
CR (1) CR6736A (en)
CZ (1) CZ20022929A3 (en)
DZ (1) DZ3308A1 (en)
EA (1) EA200200802A1 (en)
EE (1) EE200200506A (en)
GT (1) GT200100037A (en)
HN (1) HN2001000040A (en)
HR (1) HRP20020798A2 (en)
HU (1) HUP0300136A2 (en)
IL (1) IL151480A0 (en)
IS (1) IS6524A (en)
MA (1) MA26881A1 (en)
MX (1) MXPA02008535A (en)
NO (1) NO20024235L (en)
NZ (1) NZ520962A (en)
OA (1) OA12227A (en)
PA (1) PA8513201A1 (en)
PE (1) PE20011177A1 (en)
PL (1) PL358271A1 (en)
SK (1) SK12472002A3 (en)
SV (1) SV2001000338A (en)
TN (1) TNSN01036A1 (en)
WO (1) WO2001070741A1 (en)
YU (1) YU66502A (en)
ZA (1) ZA200207110B (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CZ20031125A3 (en) 2000-10-23 2003-10-15 Smithkline Beecham Corporation Novel compounds
NZ526961A (en) * 2001-02-12 2005-03-24 F 6-substituted pyrido-pyrimidines
EP1364950A4 (en) * 2001-02-26 2005-03-09 Tanabe Seiyaku Co Pyridopyrimidine or naphthyridine derivative
US20030100572A1 (en) * 2001-06-21 2003-05-29 Ariad Pharmaceuticals,Inc. Novel pyridopyrimidones and uses thereof
US20030105115A1 (en) * 2001-06-21 2003-06-05 Metcalf Chester A. Novel pyridopyrimidines and uses thereof
EA007395B3 (en) * 2002-01-22 2018-02-28 Уорнер-Ламберт Компани Ллс 2-(PYRIDINE-2-YLAMINO)PYRIDO[2,3-d]PYRIMIDIN-7-ONES
PL373339A1 (en) 2002-04-19 2005-08-22 Smithkline Beecham Corporation Novel compounds
CA2494061C (en) 2002-07-31 2011-06-14 Wayne R. Danter Protein tyrosine kinase inhibitors
ATE380810T1 (en) 2002-10-09 2007-12-15 Critical Outcome Technologies PROTEIN TYROSINE KINASE INHIBITORS
WO2004065378A1 (en) * 2003-01-17 2004-08-05 Warner-Lambert Company Llc 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
AU2004268621C1 (en) 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
WO2005047284A1 (en) 2003-11-13 2005-05-26 F. Hoffmann-La Roche Ag Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
DE102004029784A1 (en) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments
DE102004033670A1 (en) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pyridodihydropyrazinone, process for its preparation and its use as a medicament
FR2873118B1 (en) 2004-07-15 2007-11-23 Sanofi Synthelabo PYRIDO-PYRIMIDINE DERIVATIVES, THEIR APPLICATION IN THERAPEUTICS
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
EP1630163A1 (en) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, methods for their preparation and their use as drugs
CA2575804A1 (en) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
DE102004058337A1 (en) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of fused piperazin-2-one derivatives
AU2006204724A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
EP1868612A4 (en) 2005-03-25 2010-03-24 Glaxo Group Ltd Novel compounds
UY29440A1 (en) 2005-03-25 2006-10-02 Glaxo Group Ltd NEW COMPOUNDS
MX2007012951A (en) 2005-03-25 2008-01-11 Glaxo Group Ltd Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives.
PE20061193A1 (en) 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVATIVES OF 3,4-DIHYDROPYRIMIDO [4,5-d] PYRIMIDIN-2- [1H] -0NA AS KINASE INHIBITORS p38
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (en) * 2005-07-01 2007-09-07 Sanofi Aventis Sa PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
EA016945B1 (en) * 2005-10-07 2012-08-30 Экселиксис, Инк. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
CA2624965A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k.alpha.
FR2896246B1 (en) 2006-01-13 2008-08-15 Sanofi Aventis Sa PYRIDO-PYRIMIDONE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
ES2366489T3 (en) 2006-09-15 2011-10-20 Pfizer Products Inc. PIRID COMPOUND (2,3-D) PIRIDINONE AND ITS USE AS PI3 INHIBITORS.
BRPI0715566A2 (en) * 2006-10-16 2013-07-02 Gpc Biotech Inc compound, prodrug, pharmaceutical composition, use of a compound, method for inhibiting cell proliferation and method for synthesizing a compound
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
US20080114007A1 (en) * 2006-10-31 2008-05-15 Player Mark R 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
FR2910813B1 (en) 2006-12-28 2009-02-06 Sanofi Aventis Sa NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA
BRPI0809998B8 (en) * 2007-04-03 2021-05-25 Array Biopharma Inc imidazo[1,2-a]pyridine compound as receptor tyrosine kinase inhibitors, their uses, their preparation processes and pharmaceutical compositions
JP5129812B2 (en) 2007-06-15 2013-01-30 Ｍｓｄ株式会社 Bicycloaniline derivatives
WO2009019205A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
CN101945867A (en) 2007-12-19 2011-01-12 安姆根有限公司 Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
WO2009079797A1 (en) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
EP2278973B1 (en) 2008-04-07 2011-11-02 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
EP3023426A1 (en) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
UY32153A (en) 2008-09-30 2011-04-29 Exelixis Inc PY13KA (ALFA) AND MTOR PYRIDOMIDINONE INHIBITORS
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
JP2013507395A (en) * 2009-10-09 2013-03-04 アフラクシス・インコーポレイテッド 8-Ethyl-6- (aryl) pyrido [2,3-D] pyrimidin-7 (8H) -one for the treatment of CNS disorders
CA2784749C (en) 2009-12-18 2017-12-12 E. Premkumar Reddy Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
US8901137B2 (en) 2010-02-09 2014-12-02 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
CA2794952C (en) 2010-04-01 2018-05-15 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
NZ606281A (en) 2010-08-05 2014-09-26 Univ Temple 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
WO2012074951A1 (en) 2010-11-29 2012-06-07 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
ES2543569T3 (en) 2011-03-23 2015-08-20 Amgen Inc. Dual condensed tricyclic inhibitors of CDK 4/6 and FLT3
CA2836410C (en) * 2011-05-17 2019-08-20 Principia Biopharma Inc. Tyrosine kinase inhibitors
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
MX2014010176A (en) 2012-02-23 2014-11-10 Abbvie Inc Pyridopyrimidinone inhibitors of kinases.
PT2958916T (en) * 2013-02-21 2018-11-21 Pfizer Solid forms of a selective cdk4/6 inhibitor
JP2016525532A (en) 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Treatment of myelodysplastic syndrome
WO2016015597A1 (en) * 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI646094B (en) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
LT3497103T (en) 2016-08-15 2021-07-26 Pfizer Inc. Pyridopyrimdinone cdk2/4/6 inhibitors
CN110809576B (en) * 2017-03-03 2022-08-30 奥克兰联合服务有限公司 FGFR kinase inhibitor and pharmaceutical use
KR20200131246A (en) 2018-02-15 2020-11-23 누베이션 바이오 인크. Heterocyclic compounds as kinase inhibitors
CN113166148B (en) * 2018-12-07 2024-04-12 杭州英创医药科技有限公司 Heterocyclic compounds as CDK-HDAC dual pathway inhibitors
CN112759589B (en) * 2019-11-01 2022-04-08 暨南大学 Pyrimidopyridinones and their use
US11697648B2 (en) 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors
JP2024508901A (en) * 2021-03-08 2024-02-28 曁南大学 Pyridopyrimidine compounds and their uses
CN117720531A (en) * 2022-09-16 2024-03-19 华东师范大学 Pyridopyrimidine derivatives as RSK inhibitors and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
EP0964864B1 (en) * 1997-02-05 2008-04-09 Warner-Lambert Company LLC Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
ES2310039T3 (en) * 1998-05-26 2008-12-16 Warner-Lambert Company Llc BICYCLE PYRIMIDINES AND BICYCLE 3,4-DIHYDROPIRIMIDINS AS INHIBITORS OF CELL PROLIFERATION.

Also Published As

Publication number Publication date
CA2401368A1 (en) 2001-09-27
KR20020075805A (en) 2002-10-05
EE200200506A (en) 2004-02-16
HRP20020798A2 (en) 2004-02-29
HUP0300136A2 (en) 2003-05-28
SK12472002A3 (en) 2003-04-01
IL151480A0 (en) 2003-04-10
CZ20022929A3 (en) 2003-02-12
WO2001070741A1 (en) 2001-09-27
JP2003528101A (en) 2003-09-24
DZ3308A1 (en) 2001-09-27
EA200200802A1 (en) 2003-02-27
NZ520962A (en) 2003-09-26
PE20011177A1 (en) 2001-11-23
AR034119A1 (en) 2004-02-04
CR6736A (en) 2004-03-10
NO20024235D0 (en) 2002-09-05
NO20024235L (en) 2002-11-05
PL358271A1 (en) 2004-08-09
PA8513201A1 (en) 2003-06-30
BG107161A (en) 2003-06-30
SV2001000338A (en) 2001-11-30
EP1268476A1 (en) 2003-01-02
MXPA02008535A (en) 2002-12-13
IS6524A (en) 2002-08-23
ZA200207110B (en) 2003-12-04
GT200100037A (en) 2002-03-04
MA26881A1 (en) 2004-12-20
TNSN01036A1 (en) 2005-11-10
CN1422268A (en) 2003-06-04
AU2001233028A1 (en) 2001-10-03
YU66502A (en) 2005-09-19
BR0109056A (en) 2003-06-03
HN2001000040A (en) 2001-09-06
OA12227A (en) 2004-03-18
CO5280200A1 (en) 2003-05-30

Similar Documents

Publication Publication Date Title
AP2002002643A0 (en) 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
AP2002002586A0 (en) Pyrido[2,3-d] pyrimidine-2,7-diamine kinase inhibitors.
AP2000001964A0 (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation.
DK0783505T3 (en) Pyrrolo [2,3-d] pyrimidines and their use
TR200102001T2 (en) Pyrazoles substituted as P38 kinase inhibitors
GEP20063915B (en) PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
BG106594A (en) Pteridinones as kinase inhibitors
TNSN07281A1 (en) Pyrazole derivatives for the inhibition of cdk's and gsk's
NZ516292A (en) Pyrrolotriazine inhibitors of kinases
TW200744604A (en) P38 MAP kinase inhibitors and methods for using the same
NZ533310A (en) Benzimidazoles useful as protein kinase inhibitors
BR9814124A (en) Aminothiazole inhibitors of cyclin-dependent kinases
MXPA05013349A (en) 2-aminopyrimidine derivatives as raf kinase inhibitors.
RS20050732A (en) Substituted pyrimidinones
DK1123296T3 (en) Pyrazolopyrimidinone cGMP PDE5 Inhibitors for the Treatment of Sexual Disorder
ATE79380T1 (en) 2-SUBSTITUTED-E-CONDENSED(1,2,4>TRIAZOLO(1,5-C>PYRIMIDINES, PHARMACEUTICAL PREPARATIONS AND THEIR USE.
ATE389653T1 (en) 4-SUBSTITUTED DERIVATIVES OF PYRAZOLO 3,4-D PYRIMIDINE AND USES THEREOF
DK1303512T3 (en) Process for the preparation of arylacetylaminothiazoles
MEP12108A (en) Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them
DOP2001000226A (en) PROCESS FOR PREPARING 2- (4-PIRIDIL) AMINO-6-DIALQUI- LOXIFENIL-PIRIDO [2,3-D] PIRIMIDIN-7-ONAS (PROCESS FOR PREPARING 2- (4-PYRIDIL) AMINO-6-DIALKYPHENYL-PYRIDO 2 , 3-D]
WO2002087587A3 (en) 4-aminosulfonylquinazolines and -quinolines as tyrosine kinase inhibitors
MY139848A (en) Pyrazole derivatives for the inhibition of cdk's and gsk's
MX9708177A (en) Quinazoline derivatives.
TW200510315A (en) Process for the prepatation of 1-(6-methylpyridin-3-yl)-2-[(4-(methylsulphonyl)phenyl]ethanone